This trial will test whether the drug MGL-3196 can help treat NASH and prevent it from progressing to more serious liver diseases.
4 Primary · 3 Secondary · Reporting Duration: up to 54 months
Active Control
Non-Treatment Group
2000 Total Participants · 3 Treatment Groups
Primary Treatment: 100 mg MGL-3196 · Has Placebo Group · Phase 3
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Tennessee | 25.0% |
Missouri | 25.0% |
California | 25.0% |
Other | 25.0% |
18 - 65 | 100.0% |
Ruane Clinical Research | 33.3% |
Miami Dade Medical Research Institute | 33.3% |
Saint Louis University | 33.3% |
Did not meet criteria | 25.0% |
Met criteria | 75.0% |
3+ | 100.0% |
Phone Call | 100.0% |